SEC For	m 4 FORM	4 U	NITED) STAT	ES S	SECI				XCHAN	IGE (COM	MIS	SIOI	N			
to Section 16. Form 4 or Form 5 obligations may continue. See					Washington, D.C. 20549 IT OF CHANGES IN BENEFICIAL OWN pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								RSH	OMB Estim	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person* <u>HO WILLIAM</u> (Last) (First) (Middle)					RAI 3. Dat	2. Issuer Name and Ticker or Trading Symbol RAPT Therapeutics, Inc. [RAPT] 3. Date of Earliest Transaction (Month/Day/Year) 09/20/2021							. Relationship of Reporting Person(s) to Issuer Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Medical Officer				wner	
C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE (Street) SOUTH SAN CA 94080					4. If Amendment, Date of Original Filed (Month/Day/Year)							 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person 						
FRANC	ISCO	ate) (ž	(Zip)			ive Securities Acquired, Disposed of, or Beneficial								Form filed by More than One Reporting Person				
1. Title of Security (Instr. 3) (Month/Da					ction	tion 2A. Deemed Execution Date,		3. Transaction Code (Instr. 8)		4. Securitie Disposed (5)	ies Acquired (A) Of (D) (Instr. 3, 4		or \$ and \$ and \$ curities \$ Beneficially Owned Follow Reported Transporting(unt of ies :ially Following ed	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock 09/20/2					2021	021		Code S ⁽¹⁾	v	Amount 2,000	(D) D		e (Instr. 3		and 4)		D	
		Tal								osed of, o onvertibl				wneo	k			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,		Transaction o Code (Instr. D 8) A (/ D 0 (I		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date E Expiratio (Month/I	on Da		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4) Amou		Derivative d Security S (Instr. 5) B F R T (I		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(S) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownershi (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.

2. The total amount of beneficially owned shares is amended to correct misinformation provided by the broker. 2,000 shares reported as sold on 9/17/2021 were not sold and were subsequently sold on 9/20/2021.

(A) (D) Date

Exercisable

Remarks:

/s/ Rodney Young, Attorney-09/22/2021 in-Fact for William Ho

or Number

of

Shares

Title

Expiration Date

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code v

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.